Immunome, Inc. · NASDAQ:IMNM

Immunome — Investor Presentation (February 2022)

38 slides from Immunome's investor presentation, Feb 8, 2022

Slide 1: Harnessing the Power of The Human Memory B Cell
Harnessing the Power of The Human Memory B Cell February 8, 2022 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com Copyright © 2022 Immunome, Inc. All rights reserved.
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation includes certain disclosures that contain “forward-looking All statements contained in this document are made as of the date specified on the cover, statements” intended to qualify for the “safe harbor” from liability established by the an
Slide 3: Experienced Management Team
Experienced Management Team Purnanand Sarma, PhD Former CEO of Taris Biomedical President & CEO Sold to Johnson & Johnson in 2019 Corleen Roche Former US CFO Biogen Chief Financial Officer Former CFO, Global Vaccines, Wyeth/Pfizer Dennis Giesing, PhD Former CSO at Taris Biomedical Chief Development
Slide 4: Proprietary Discovery Engine "At A Glance"
Immunome ADVANCING CLINICAL PROGRAMS AND ANTICIPATED MILESTONES “At A Glance” IMM-BCP-01 Treatment of COVID-19 Topline Data 1H 2022 • Three antibody cocktail • Targets three non-overlapping regions of the spike protein • ACE2 and Non ACE2 dependent neutralization Proprietary • IMM20253 exhibits a no
Slide 5: Immunome Development Pipeline and Anticipated Key Milestones
Immunome Development Pipeline and Anticipated Key Milestones PRODUCT CANDIDATE ANTICIPATED ANTI-INFECTIVES TARGET DISCOVERY PRECLINICAL DESCRIPTION MILESTONE Three SARS- Three antibody Topline Data in IMM-BCP-01 CoV-2 Epitopes cocktail 1H 2022* PRODUCT CANDIDATE ANTICIPATED ONCOLOGY TARGET DISCOVERY
Slide 6: Proprietary Discovery Engine Patient Sampling
Proprietary Discovery Engine Patient Sampling Ongoing access to new and diverse patient memory B cells to feed the engine We See Disease Through the Lens of a B cell Patient Response Capture memory B cells from cancer or infectious disease patients Memory B cells: The Most Antibody Screening Educate
Slide 8: Discovery Engine Enables Rapid Isolation of Antibodies Against SARS-CoV-2
Discovery Engine Enables Rapid Isolation of Antibodies Against SARS-CoV-2 Potential Application Against Other Infectious Agents Select convalescent patients Deep repertoire screening and Three antibody cocktail for potential with strong anti-viral titer characterization of antibodies prophylaxis and
Slide 9: COVID - Summary
COVID - Summary Current COVID Vaccines and Antibody Therapeutics Not Sufficient • Breakthrough infections despite vaccine use1 • FDA Emergency Use Authorization of antibody therapeutics for treatment of mild to moderate COVID-192 • First-generation antibody therapeutics developed based on virus neut
Slide 10: COVID-19 Therapeutics Will Remain Critical
COVID-19 Therapeutics Will Remain Critical Variants will likely continue to emerge, and may rapidly change the landscape • Omicron variant encompasses >99% of all U.S. cases since discovery in November ‘21 • CDC and WHO continually monitoring for new variants that have the potential to change the la
Slide 11: IMM-BCP-01 Cocktail Leverages Multiple Mechanisms of Action
IMM-BCP-01 Cocktail Leverages Multiple Mechanisms of Action Bamlanivimab IMM-BCP-01 Regen-CoV AZD7442 Sotrovimab ADG20 & Etesevimab ACE2 Dependent Neutralization Non ACE2 Dependent * Neutralization Viral Clearance In vivo Potency*** (neutralization + viral clearance) * Immunome’s antibody broadly sy
Slide 12: IMM-BCP-01: Leverages Unique and Cryptic Epitopes
IMM-BCP-01: Leverages Unique and Cryptic Epitopes EPITOPE 3: IMM20190 (ACE2 Dependent) EPITOPE 1: IMM20253 • Antibody is a potent ACE2 competitor (Non-ACE2 Dependent) • A composite epitope involving the • Broadly conserved across receptor binding ridge and an area all SARS-CoV-2 strains and adjacent
Slide 13: IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms
IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms Induces Protease Sensitive Conformation Spike + Spike + Spike + Spike ACE2 IMM20253 IMM20190 CONFORMATIONAL CHANGE AND S2 RELEASE - 15 60 - 15 60 - 15 60 15 60 2 (S1 +S2) IMM20253 S2 1 ACE2 IMM20190 BLOCKADE + IMM20184 Compete ACE2 Binding
Slide 14: Multiple Mechanisms Drive Superior Preclinical Efficacy
Multiple Mechanisms Drive Superior Preclinical Efficacy Sotrovimab IMM-BCP-01 (EUA Approved at 500 mg Dose) • Prophylactic setting (Day -1) in infected hamsters • Prophylactic setting (Day -1) in infected hamsters • ~2.2 log clearance at 3 mg/kg (total Ab) • ~ 2-log clearance at 5mg/kg • ~4 log clea
Slide 15: Multi-Modal Activity Elicits Robust Efficacy
Multi-Modal Activity Elicits Robust Efficacy REF (WA1/2020) Infected Hamster Model in Treatment Setting REF (WA1/2020) • ~3-log reduction at 3 mg/kg dose • IMM-BCP-01 exhibits typical IgG1 clearance » Dose range (3 – 15 mg/kg total Ab) yielded estimated Cmax values between 40 – 200 mg/mL (0.3 – 1.3
Slide 16: Multiple Neutralization Mechanisms Induce Combinatorial Effect
Multiple Neutralization Mechanisms Induce Combinatorial Effect IMM-BCP-01 is Active Across Variants IMM-BCP-01 Acts Additively and IMM-BCP-01 Neutralization of Pseudovirus1 Synergistically to Neutralize Variants1 IMM-BCP-01 Neutralizes Broad Array of Variants Cmax2 Alpha • Activity maintained over 2
Slide 17: IMM-BCP-01 Exhibits Broad Neutralization Across Live Virus Variants
IMM-BCP-01 Exhibits Broad Neutralization Across Live Virus Variants Retains Neutralization Activity Against Neutralizes Prior Variants of Concern Omicron1 SARS-CoV-2Isolates SARS-CoV-2 Isolates WA1/2020 (PFU, VeroE6) Omicron (PFU, VeroE6) IMM-BCP-01 (1:1:1) IMM20190/184/253 120 120 125 100 S309 IMM2
Slide 18: Viral Clearance Mechanisms Are Necessary to Maintain Therapeutic Efficacy
Viral Clearance Mechanisms Are Necessary to Neutralization is not sufficient in treatment setting Maintain » Mutating the Fc domain (LALA-PG) of anti-Spike antibodies Therapeutic Efficacy does not alter in vitro neutralization potency, but destroys efficacy in a mouse treatment model of COVID-19 Neu
Slide 19: IMM-BCP-01: Non-Neutralization Mechanisms Directed at Viral Clearance
IMM-BCP-01: Non-Neutralization Mechanisms Directed at Viral Clearance PHAGOCYTOSIS NEUTRALIZATION PHAGOCYTE (M∅) ANTIBODY-DEPENDENT CELLULAR CTYOTOXICITY COMPLEMENT FIXATION NK CELL C1q VIRAL TARGET VIRALLY-INFECTED CELL (intracellular) Copyright © 2022 Immunome, Inc. All rights reserved. 19
Slide 20: In Vitro Data Shows Potential for Multiple Viral Clearance Mechanisms In Vivo
In Vitro Data Shows Potential for Multiple Viral Clearance Mechanisms In Vivo Antibody-Dependent Complement Fixation Phagocytosis Cellular Cytotoxicity IMM20184 IMM20190 IMM20253 Cmax1 Cmax1 Cmax1 IMM20184/253 IMM-BCP-01 Isotype 1. Hamster Cmax (total antibody); based upon 9 m/kg dose in hamster • A
Slide 21: IMM-BCP-01 Summary
IMM-BCP-01 Summary Broad Activity Across Variants • Multi-modal MOA; Antibodies directed at non- overlapping/ conserved epitopes provide broad coverage Synergy Enabled by Cocktail Approach • Antibody synergy across neutralization and non- neutralization mechanisms. Clearance by phagocytosis and comp
Slide 23: Oncology – Key messages
Oncology – Key messages Highly disruptive platform discovering novel targets through function-based interrogation of patient memory B cell response to tumors • Among ~2,400 hits from historical screening, ~150 recombinant mAbs were characterized, >70 novel targets/antibodies were identified to-date
Slide 24: Proprietary Discovery Engine Patient Sampling
Proprietary Discovery Engine Patient Sampling Ongoing access to new and diverse patient memory B cells to feed the engine We See Disease Through the Lens of a B cell Patient Response Capture memory B cells from cancer or infectious disease patients Memory B cells: The Most Antibody Screening Educate
Slide 25: Human Antibody Response Against Tumor in Patients
Human Antibody Response Against Tumor in Patients Advantages of the Immunome Platform Applicable Across Broad Diverse B Cell Clones Targeting Unique Features on Cancer Cells Cancer Indications NORMAL CANCER Ectopic expression CANCER A Mis-folded CANCER B Protein Alternate Splicing CANCER C CANCER X
Slide 26: Novel Insights from Discovery Engine
Novel Insights from Discovery Engine Systematic Mining of Antibodies Reveal Disease Relevant Functional Clusters Diverse Cancer Landscape 14 >350 ~140 ~250K Cancers Patients Libraries Hybridoma Immune Modulation Novel Targets A Highly Productive Platform Discovery Engine Extracellular Matrix ~2400*
Slide 27: Immunome Oncology R&D Pipeline
Immunome Oncology R&D Pipeline Targets Identified from Patient Antibodies Program Novel Immune Modulators Potential Cancers of Relevance Format IMM-ONC-01 Neutralize apoptotic tumor cells derived IL-38; recruit and Lung, head & neck, gastroesophageal mAb (Anti-IL-38) activate immune cells Target Res
Slide 28: IL-38: A Novel Oncology Target
IL-38: A Novel Oncology Target IL-38 Dampens Innate Anti-Tumor Immunity Typical Inflammatory Anti-tumor Response Productive Immune Response IL-38 AGONISTS ANTAGONISTS IL-381 PD-1/PD-L1 IL36a IL36b IL36Ra IL36g IL38 Tumor Microenvironment Autoimmunity Immune Immune Desert Pre-Inflamed Inflamed Exhaus
Slide 29: Clinical Consequences of IL-38 Expression
Clinical Consequences of IL-38 Expression Potential for IL-38 Combination Studies with Existing Therapies Inverse Relationship Between IL-38 Expression Tumor Cells Secrete IL-38 Upon and Immune Cell Infiltration in Tumors Apoptosis Induction • IL-38 secretion associated with apoptotic cell death1 •
Slide 30: IL-38 Expression in Solid Tumors
IL-38 Expression in Solid Tumors IL-38 is Expressed in Multiple Tumors of High Unmet Medical Need IL-38 is Expressed in Multiple Tumors IL-38 Expression in Multiple Cancer Types of High Unmet Medical Need Confirmed in Real-World Data* Head & Neck Esophagus Lung, Squamous Cervix 23% 53% 41% 48% • Ana
Slide 31: IL-38 Expression in Solid Tumors
Isotype Control Anti-IL-38 (Immunome Clone) D o R c0 n 3 D s0 14 o 5 4 Stage I Doc1 0264 8 D c1 0378 o 6 R c1 011 0 l 7 R a15 03 8 l 0 0 R a06 07 8 l 0 6 Rla02 07 0 7 R a09 05 l 0 4 R a11 03 l 0 7 R a13 02 l 0 6 R a13 04 l 0 2 Rla14 03 0 0 D a01 06 o 0 5 D c 0 08 o 9 8 D c0 02 oc 62 47 Stage II D 0
Slide 32: IL-38 is Associated with Reduced Immune Cell Infiltration
IL-38 Expression in Solid Tumors IL-38 is Associated with Reduced Immune Cell Infiltration IL-38 Overexpression Inhibits Infiltration High IL-38 Expression is Associated with of T cells into Tumors In Vivo Reduced Immune Cell Infiltration • IL-38 high tumor samples correlate with reduced infiltratio
Slide 33: Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models
IMM-ONC-01 Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models Demonstration of Anti-Tumor Activity Induction of Anti-Tumor Memory (B16F10 Model) (EMT6 Model) • Immunologically cold tumor model • ~40% response rate upon treatment with IMM-ONC-01 • IMM-ONC-01 significantly inhibits B1
Slide 34: IMM-ONC-01 Program Summary – Modulating Innate Anti-Tumor Immunity
IMM-ONC-01 Program Summary – Modulating Innate Anti-Tumor Immunity IMM-ONC-01 is a Novel Antibody Candidate Targeting IL-38 • IL-38 is a novel checkpoint in the innate immune system • Targeting IL-38 using IMM-ONC-01 expected to boost anti-tumor immunity • Preclinical research confirms the mechanism
Slide 36: Beyond Canonical Targets for ADC-based Targeting of Cancer
Beyond Canonical HER2 Targets for ADC-based TROP2 EGFR Targeting of Cancer CD19 Canonical Novel tumor antigens are Current ADC development is focused needed to help develop on canonical targets better ADCs Non-Canonical Non-canonical targets represent large portion of the cellular landscape Copyrigh
Slide 37: High Throughput Screening Platform Yields Multiple Potential Therapeutic Applications
High Throughput Screening Platform Yields Multiple Potential Therapeutic Applications HYBRIDOMA LIBRARY ANTIBODIES Binding to membrane 5,000 antibodies in quadruplets per protein array extracts or cancer cells against >100 of tumors and cell lines FACS analysis against 36 tumor Strong binding to tum
Slide 38: Proprietary Discovery Engine
Immunome ADVANCING CLINICAL PROGRAMS AND ANTICIPATED MILESTONES “At A Glance” IMM-BCP-01 Treatment of COVID-19 Topline Data 1H 2022 • Three antibody cocktail • Targets three non-overlapping regions of the spike protein • ACE2 and Non ACE2 dependent neutralization Proprietary • IMM20253 exhibits a no

Immunome — Investor Presentation (February 2022) on 6ix

Immunome — Investor Presentation (February 2022)

Slide 1: Harnessing the Power of The Human Memory B Cell

Slide 2: Disclaimers and Forward-Looking Statements

Slide 3: Experienced Management Team

Slide 4: Proprietary Discovery Engine "At A Glance"

Slide 5: Immunome Development Pipeline and Anticipated Key Milestones

Slide 6: Proprietary Discovery Engine Patient Sampling

Slide 7: Infectious Diseases

Slide 8: Discovery Engine Enables Rapid Isolation of Antibodies Against SARS-CoV-2

Slide 9: COVID - Summary

Slide 10: COVID-19 Therapeutics Will Remain Critical

Slide 11: IMM-BCP-01 Cocktail Leverages Multiple Mechanisms of Action

Slide 12: IMM-BCP-01: Leverages Unique and Cryptic Epitopes

Slide 13: IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms

Slide 14: Multiple Mechanisms Drive Superior Preclinical Efficacy

Slide 15: Multi-Modal Activity Elicits Robust Efficacy

Slide 16: Multiple Neutralization Mechanisms Induce Combinatorial Effect

Slide 17: IMM-BCP-01 Exhibits Broad Neutralization Across Live Virus Variants

Slide 18: Viral Clearance Mechanisms Are Necessary to Maintain Therapeutic Efficacy

Slide 19: IMM-BCP-01: Non-Neutralization Mechanisms Directed at Viral Clearance

Slide 20: In Vitro Data Shows Potential for Multiple Viral Clearance Mechanisms In Vivo

Slide 21: IMM-BCP-01 Summary

Slide 22: Oncology

Slide 23: Oncology – Key messages

Slide 24: Proprietary Discovery Engine Patient Sampling

Slide 25: Human Antibody Response Against Tumor in Patients

Slide 26: Novel Insights from Discovery Engine

Slide 27: Immunome Oncology R&D Pipeline

Slide 28: IL-38: A Novel Oncology Target

Slide 29: Clinical Consequences of IL-38 Expression

Slide 30: IL-38 Expression in Solid Tumors

Slide 31: IL-38 Expression in Solid Tumors

Slide 32: IL-38 is Associated with Reduced Immune Cell Infiltration

Slide 33: Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models

Slide 34: IMM-ONC-01 Program Summary – Modulating Innate Anti-Tumor Immunity

Slide 35: Oncology: Antibody Drug Conjugates

Slide 36: Beyond Canonical Targets for ADC-based Targeting of Cancer

Slide 37: High Throughput Screening Platform Yields Multiple Potential Therapeutic Applications

Slide 38: Proprietary Discovery Engine